Investigating Biomarkers of Progressive Renal Disease and Screening of Nephrotoxic Agents
Different factors may initiate or contribute to the process of Chronic Kidney Disease (CKD); in areas such as Western Europe and North America diabetes and hypertension are the major causes whereas in other parts of the world the aetiology is different with industrial pollutants or naturally occurring substances contributing greatly.
The prevalence of CKD in the UK is believed to be as high as 5- 10%; generally when this diagnosis is made the patient may have lost approximately 50% of their kidney function. However, at this point, for the majority of patients, it is often uncertain whether they will progress to complete loss of kidney function resulting in Established Renal Failure (ERF) or to determine how rapidly they might progress.
This on-going project seeks to identify novel markers and mediators of disease that may serve as useful non-invasive biomarkers of CKD progression; particularly, but not exclusively, in diabetic patients.
In parallel to the work investigating urinary biomarkers we have been seeking to establish useful panels of markers of renal damage and nephrotoxicity that can be used in our in vitro assays to test substances potentially harmful to the human kidney. Using both established and novel markers we are comparing nephrotoxic medicines such as calcineurin inhibitors and certain antibiotics with pollutants such as cadmium and biological agent such as aristolochic acid. From this data we will be able to construct a powerful screening tool that can used to quantitatively and qualitatively measure renal damage of exogenous agents.
If you would like further information on this project please contact Sarah.Yates@helierscientific.co.uk or email@example.com, or visit www.helierscientific.co.uk
back to top